Which Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based Choices

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1165-1172

  Cairns, John A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ELDERLY CARE; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY FAILURE; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; STROKE;

EID: 84884594837     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.05.010     Document Type: Review

References (51)

1. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
2. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
3. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 suppl). e531S-75S.
4. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006, 8:651-745.
5. Atrial Fibrillation Investigators Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
6. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
7. Hart R.G., Pearce L.A., Aguilar M.I. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007, 147:590-592.
8. Mant J., Hobbs R., Roalfe A., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): and randomized controlled trial. Lancet 2007, 370:493-503.
9. Hylek E.M., Evans-Molina C., Shea C., Henault L.E., Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696.
10. The ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation. NEngl J Med 2009, 360:2066-2078.
11. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S., Pogue J., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912.
12. Ageno W., Gallus A., Wittkowsky A., Crowther M., Hylek E.M., Palatereti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141. e44S-88S.
13. Wan Y., Heneghan C., Roberts P.R., et al. Anticogulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:84-91.
14. Garcia D., Regan S., Crowther M., Hughes R.A., Hylek E.M. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005, 127:2049-2056.
15. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
16. Yeh C.H., Fredenburgh J.C., Weitz J.I. Oral direct factor Xa inhibitors. Circ Res 2012, 111:1069-1078.
17. Dabigatran etexilate capsule drug product monograph. Available at: Accessed April 8,2013. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=84384%26lang=eng.
18. Rivaroxaban tablet drug product monograph. Available at: Accessed April 8,2013. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=86440%26lang=eng.
19. Apixaban tablet drug product monograph. Available at: Accessed April 8,2013. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=88264%26lang=eng.
20. Poulsen B.K., Grove E.L., Husted S.E. New oral anticoagulants. A review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012, 72:1739-1753.
21. Ruff C.T., Giugliano R.P., Antman E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
22. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013, 34:1498-1505.
23. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
24. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
25. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
26. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. New Engl J Med 2011, 364:806-817.
27. Dentali F., Riva N., Crowther M., Turpie A.G., Lip G.Y., Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012, 126:2381-2391.
28. Whitlock J.C., Sun J.D., Fremes F.E., Rubens F.D., Teoh K.H. Antithrombotic and thrombolytic therapy for valvular heart disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American Collage of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141. e576S-600S.
29. Vandvik P.O., Lincoff A.M., Gore J.M., et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American Collage of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141. e637S-668S.
30. Van de Werf F., Brueckmann M., Connolly S.J., et al. Acomparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012, 163:931-937.
31. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
32. Fox K.A.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
33. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33:2821-2830.
34. Van Spall H.G., Wallentin L., Yusuf S., et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centres and countries: an analysis of patients receiving warfarin in the RE-LY trial. Circulation 2012, 126:2309-2316.
35. Canadian Agency for Drugs and Technologies in Health. Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation (CADTH Therapeutic Review; vol. 1, no. 1b). Available at: Accessed April 12,2013. http://www.cadth.ca/media/pdf/TR0003_AntithromboticAgents-AF_ScienceReport_e.pdf.
36. Lip G.Y., Larsen T.B., Skjoth F., Rasmussen L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. JAm Coll Cardiol 2012, 60:738-746.
37. Mantha S., Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012, 108:476-484.
38. Southworth M.R., Reichman M.E., Unger E.F. Dabigatran and postmarketing reports of bleeding. NEngl J Med 2013, 368:1272-1274.
39. Larsen T.B., Rasmussen L.H., Skjøth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. JAm Coll Cardiolol 2013, 61:2264-2273.
40. Apixaban (Eliquis)-a new oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther 2013, 55:9-10.
41. Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012, 125:669-676.
42. Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012, 2. pii: e001592.
43. Cairns J.A., McMurtry M.S. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. Can J Cardiol 2013, 29(7 suppl):S60-S70.
44. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19.
45. Nieto J.A., Espada N.G., Merino R.G., González T.C. Dabigatran, rivaroxaban, and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012, 130:183-191.
46. Connors J.M. Extended treatment of venous thromboembolism. NEngl J Med 2013, 368:767-769.
47. EINSTEIN-PE Investigators, Büller H.R., Prins M.H., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. NEngl J Med 2012, 366:1287-1297.
48. Diener H.C., Connolly S.J., Ezekowitz M.D., et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163.
49. Hankey G.J., Patel M.R., Stevens S.R., et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack; a subgroup analysis of ROCKET AF. Lancet 2012, 11:315-322.
50. Easton J.D., Lopes R.D., Bahit M.C., et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012, 11:503-511.
51. Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index. Available at: https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp.